Dextropropoxyphene
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Dextropropoxyphene (propoxyphene) — sold as Darvon — is a synthetic opioid of the diphenylpropylamine class. It is a structural relative of methadone, but with far weaker analgesic potency and a narrow margin between a therapeutic and a dangerous dose. It activates opioid receptors in the brain, suppressing pain signals and producing mild sedation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized at Eli Lilly in 1953[1] and marketed from 1957 as Darvon, it became one of the most widely prescribed analgesics in the English-speaking world despite evidence it worked no better than paracetamol.[2] Overdose deaths far out of proportion to its modest benefit led regulators to act. It was withdrawn from US, UK, EU, and Australian markets between 2005 and 2010.
Subjective effects include mild pain suppression, gentle warmth, light sedation, and a quiet easing of anxiety. The experience is that of a weak, short-lived opioid — modest comfort without the heavy drowsiness or depth of stronger compounds. Nausea, dizziness, and constipation are common unwanted effects.
Dextropropoxyphene produces moderate physical and psychological dependence,[3] and fatal overdose can occur within an hour at doses only slightly above the therapeutic range.[4] A cardiotoxic metabolite — norpropoxyphene — blocks the heart's electrical signaling in a way naloxone cannot reverse, making standard opioid overdose protocols insufficient.[5] Six decades of clinical and forensic data underpin the risk profile, though no formal human LD₅₀ has been published.
History[edit]
Discovery
Dextropropoxyphene was synthesized by A. Pohland and H.R. Sullivan at Eli Lilly in 1953.[1] It was designed as a milder version of methadone — same structural backbone, lower expected abuse liability. US Patent No. 2,728,779 was granted to Eli Lilly in 1955.[6]
Prescribing era and overdose crisis
The drug reached the US market in 1957 as Darvon,[7] promoted as safer than codeine. Combination products followed — Darvocet in the US and co-proxamol (Distalgesic) in the UK. By the 1970s it ranked among the most prescribed analgesics in both countries, despite forensic evidence that overdose deaths were disproportionate to its modest clinical benefit.
Withdrawal
The UK withdrew co-proxamol in January 2005,[8] the EU followed in 2008, and the US FDA requested voluntary market withdrawal in November 2010 citing cardiac abnormalities at therapeutic doses.[9] Australia removed it from its therapeutic register around the same time. The UK withdrawal is estimated to have prevented 300–400 overdose deaths per year in England and Wales.[10]
The brand name Darvon became synonymous in American culture with casual prescription painkiller use during the 1970s and 1980s. Co-proxamol acquired a grimmer reputation in British forensic medicine — coroners in the West Midlands identified Distalgesic as the single most common cause of fatal drug overdose in their region,[4] and its role in completed suicides made it a defining case study in means restriction as a public health tool.
Chemistry[edit]
Structural class
Dextropropoxyphene belongs to the diphenylpropylamine family of synthetic opioids — the same structural lineage as methadone. Its molecular formula is C₂₂H₂₉NO₂ (molecular weight 339.5 g/mol). A propanoate ester group — in place of the ketone found in methadone — contributes to its weaker receptor binding.
Stereochemistry
The molecule exists in two mirror-image forms. Only the dextropropoxyphene form produces analgesia; its mirror image, levopropoxyphene, has only a cough-suppressant effect.[6] Two pharmaceutical salt forms were marketed: propoxyphene hydrochloride (65 mg capsules) and propoxyphene napsylate (100 mg tablets). A 100 mg napsylate dose is equivalent in analgesic effect to 65 mg hydrochloride[7] — the two salts are not interchangeable by weight.
Pharmacology[edit]
Mechanism of action
Dextropropoxyphene activates mu-opioid receptors with unusually low binding affinity — among the weakest of any approved opioid.[11] Despite this, it behaves differently from morphine: animals tolerant to morphine's pain-relieving effects retain full sensitivity to dextropropoxyphene,[12] suggesting it engages slightly different signaling pathways.
Two separate cardiac effects can prove fatal — neither reversed by naloxone. The parent compound blocks sodium channels in the heart, slowing electrical conduction and widening the QRS complex.[13] The metabolite norpropoxyphene blocks potassium channels responsible for resetting the heart's rhythm after each beat, risking fatal irregular rhythms.[5]
Pharmacokinetics
The liver converts dextropropoxyphene to norpropoxyphene via CYP3A4.[14] Norpropoxyphene has a half-life of 30–36 hours — up to 76 hours in elderly patients[15] — so it accumulates significantly with repeated dosing. Genetic variation in CYP3A5 can raise peak drug levels by 75–83% at the same dose,[16] which helps explain why toxicity is unpredictable across individuals.
Neuroscience[edit]
Where it acts
Dextropropoxyphene activates the brain's mesolimbic pathway by freeing dopamine in the nucleus accumbens.[7] Pain relief occurs through a separate descending pathway from brain to spinal cord. Systematic reviews found its pain-relieving effect equivalent to paracetamol alone,[2] suggesting limited functional engagement of this pathway at therapeutic doses.
Why it matters
The drug's paradox: abuse potential that exceeds what its weak analgesia would predict. It appears to engage the brain's pleasure signal more readily than its motivational drive — producing a modest hedonic effect that fades quickly, which may explain the compulsive redosing pattern seen in dependence.[3]
Whether dextropropoxyphene's sodium channel effects contribute independently to analgesia remains untested.[13] Its differential tolerance profile compared to morphine[12] suggests engagement of distinct receptor populations, but this has not been characterized at the molecular level. The weak serotonin reuptake activity[17] raises unanswered questions about whether serotonergic tone shapes the warmth and anxiolysis users report.
Subjective Effects[edit]
Dextropropoxyphene produces a subdued opioid experience — gentle warmth, light physical sedation, and a quiet narrowing of mental activity. It is defined more by what it removes than what it adds: a lowering of pain and anxiety rather than any pronounced euphoria or depth.
Compared to codeine, it is milder and less reliably analgesic. Alongside tramadol, it sits in a similar tier among the weakest clinical opioids. Its defining characteristic is not what it offers experientially but what it costs — a disproportionate toxicity profile relative to its modest subjective effects.[2]
Effect Grid
At 65–100 mg oral (the standard therapeutic dose range as hydrochloride salt), moderate opioid warmth, sedation, and mild cognitive euphoria are present. Anxiety suppression is noticeable. Thought deceleration and emotional suppression create a sense of mental quieting. Some users report a modest tactile euphoria — a diffuse bodily comfort characteristic of weak opioid agonism.
Nausea, constipation, and dizziness are common at this tier. Pupil constriction (miosis) is observable. Respiratory depression is present but subclinical in healthy individuals at this dose. Dry mouth may occur due to mild anticholinergic activity.
The analgesic effect peaks at this tier but remains equivalent to paracetamol alone. Norpropoxyphene (half-life 30–36 hours) begins accumulating with repeated dosing, introducing cardiac risk independent of subjective tolerance.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Breathing alteration · Constipation · Muscle relaxation · Bodily heaviness · Body high · Dizziness · Nausea · Physical fatigue · Tactile euphoria · Abnormal heartbeat · Dry mouth · Excessive sweating · Headache · Vomiting · Yawning · Seizure threshold reduction
Bodily heaviness · Body high · Dizziness · Nausea · Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Headache · Vomiting · Yawning · Seizure threshold reduction
Information processing suppression · Cognitive euphoria · Confusion · Thought deceleration · Delusions of sobriety · Delirium
Thought deceleration · Delirium
Timeline
Initial warmth and mild anxiolysis as plasma concentrations rise. Subtle bodily relaxation begins within 20–30 minutes of oral ingestion.
Maximum opioid effects — sedation, cognitive euphoria, pain suppression, miosis. Corresponds to Tmax of 1–2 hours with sustained effects through 4 hours at standard doses.
Gradual decline of subjective effects with residual sedation and possible nausea. Norpropoxyphene continues to accumulate systemically with a 30–36 hour half-life, maintaining cardiac risk beyond subjective awareness.
⚠ Avoid driving or operating machinery for at least 6 hours after dosing — residual sedation and impaired reaction time may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Acute overdose
Fatal overdose occurs rapidly. Death within one hour of ingestion has been documented repeatedly, often before medical intervention is possible.[4][18][19] The fatal dose can be as low as approximately fifteen co-proxamol tablets, and alcohol lowers this threshold further.[4]
Overdose presents with coma, stopped or severely slowed breathing, vomiting, seizures, and cardiovascular collapse. No formal human LD₅₀ has been published.safety citation needed
Heart toxicity
Two distinct cardiac mechanisms drive toxicity — neither reversed by naloxone:
- Sodium channel blockade by the parent compound causes progressive widening of the QRS complex, with recovery roughly ten times slower than lidocaine[13]
- Potassium channel blockade by norpropoxyphene prolongs the QT interval, risking fatal irregular heart rhythms[5]
Norpropoxyphene's half-life of 30–36 hours (up to 76 hours in elderly patients[15]) means cardiac risk persists long after breathing has been stabilized. The FDA cited cardiac abnormalities at recommended therapeutic doses as grounds for withdrawal.[9]
Alcohol synergism
Alcohol dramatically amplifies toxicity. Blood concentrations survivable alone become fatal with co-ingestion.[20][21] Middle-aged men faced the highest risk of non-suicidal dextropropoxyphene-alcohol death.[22]
Kidney failure
Norpropoxyphene accumulates to toxic levels in kidney failure. Dextropropoxyphene is contraindicated in chronic kidney disease.[23]
Public health impact
Co-proxamol accounted for 18% of drug-related suicides in England and Wales during 1997–1999, representing 5% of all suicides nationally.[19] In Sweden it was the most common drug found in fatal self-inflicted poisoning.[24] The UK withdrawal reduced estimated overdose deaths by 300–400 per year.[10]
Psychological risks
Confusion and cognitive impairment occur in elderly patients at therapeutic doses, driven by drug accumulation at dramatically prolonged half-lives.[15] Hallucinations have been reported as an adverse effect.[25]
The primary psychological risk is contribution to completed suicide — driven by rapid lethality in overdose, ease of access, and availability in quantities sufficient for self-harm.[19][26]
Tolerance & dependence
Tolerance to analgesic and euphoric effects develops with repeated use.[3] Cross-tolerance with morphine appears incomplete.[12]
A critical hazard: norpropoxyphene accumulates independently of opioid tolerance. The cardiac risk does not plateau as subjective tolerance grows — increasing the dose to chase the same effect raises cardiac danger without warning. Both physical and psychological dependence are documented, and abuse potential was consistently underestimated during the prescribing era.[7]
Drug interactions
Lethal combinations
Alcohol is the best-documented lethal combination: concentrations survivable alone become fatal with co-ingestion.[20][21] Benzodiazepines, other opioids, GHB/GBL, and ketamine add to respiratory and cardiovascular depression.safety citation needed
Enzyme inhibition
Dextropropoxyphene potently inhibits CYP2D6,[7] raising blood levels of drugs cleared by this enzyme:
- Metoprolol: life-threatening heart rate of ~30 bpm has been documented[27]
- Carbamazepine: elevated levels risking toxicity[28]
- Tricyclic antidepressants: elevated levels with additive cardiac toxicity risk
- Warfarin: enhanced blood-thinning effect
- Alprazolam: impaired clearance[29]
Serotonin toxicity
Combining with monoamine oxidase inhibitors (phenelzine, tranylcypromine, linezolid, moclobemide) can trigger dangerous serotonin overload — an overheating and seizure response that can be fatal.[17]
Contraindications
Absolute
- Alcohol or CNS depressants (benzodiazepines, other opioids, GHB/GBL, barbiturates): synergistic respiratory and cardiac depression; alcohol lowers the fatal dose to otherwise survivable levels[20]
- Monoamine oxidase inhibitors: risk of fatal serotonin syndrome[17]
- Chronic kidney failure: norpropoxyphene accumulates to toxic concentrations[23]
- Pre-existing heart conduction abnormalities (prolonged QTc, bundle branch block, arrhythmia history): propoxyphene and norpropoxyphene worsen both sodium and potassium channel dysfunction[5][13]
Relative
- Elderly patients: half-life 5–10 times longer than in younger adults produces dangerous accumulation[15]
- Liver impairment: reduced clearance alters the parent-to-metabolite ratio[25]
- Respiratory disease (COPD, sleep apnea): opioid respiratory depression compounds existing breathing problems
- QT-prolonging medications (antipsychotics, certain antibiotics, class III antiarrhythmics): additive QT risk via norpropoxyphene[5]
- CYP2D6 substrate medications (metoprolol, tricyclic antidepressants): enzyme inhibition raises co-administered drug levels[27]
- CYP3A5 poor expressers (CYP3A5*3/*3 genotype): approximately 75–83% higher drug exposure at any given dose[16]
Harm Reduction[edit]
Forms & Identification
Dextropropoxyphene has been withdrawn from all major pharmaceutical markets. Any product encountered today is either diverted legacy stock or sourced from unregulated markets in jurisdictions where withdrawal was not enforced.
Old stock may have degraded unpredictably — the propanoate ester is susceptible to hydrolysis, altering both potency and impurity profile.
The two salt forms are not interchangeable by weight: 100 mg napsylate equals 65 mg hydrochloride in analgesic effect.[7] Confusing the two salts can cause unintentional overdose. Authentic pharmaceutical forms were always oral tablets or capsules — no injection or insufflation formulation ever existed.
Guidelines
- Never combine with alcohol under any circumstances — doses survivable alone become fatal with co-ingestion[20]
- Never exceed the therapeutic dose range (65 mg hydrochloride / 100 mg napsylate per dose)
- Allow minimum 4–6 hours between doses to avoid norpropoxyphene accumulation
- Ensure someone present knows what was taken, when, and how much
- Do not use if taking MAOIs, benzodiazepines, other opioids, or any QT-prolonging medication
- Individuals of unknown CYP3A5 genotype should assume higher sensitivity — start at the lowest effective dose[16]
- Never redose based on perceived tolerance — cardiotoxic metabolite accumulation proceeds independently of subjective opioid tolerance
Set & Setting
The primary risk is physiological collapse — cardiac arrest or respiratory failure occurring within one hour of an excessive dose.[4]
Never use alone. A sober observer who knows what was taken and can call emergency services is the single most important harm reduction measure for this substance.
Aftercare & integration. Norpropoxyphene persists in the body for 30–36 hours after the last dose (longer in older adults). Cardiac vulnerability continues during this period even after subjective effects have resolved. Avoid alcohol, other depressants, and physical exertion for at least 48 hours after the last dose.
If repeated use has occurred, monitor for early withdrawal signs — anxiety, insomnia, muscle aches, gut distress — beginning 12–24 hours after the last dose. These are manageable but indicate developing dependence.
Recovery & Support
Physical withdrawal peaks within 48–72 hours and resolves over 7–14 days, but psychological craving and disrupted sleep may persist for weeks. Medical supervision during withdrawal is recommended — accumulated norpropoxyphene creates cardiac risk in the early withdrawal period.
Opioid-specific resources include SMART Recovery, Narcotics Anonymous, and medically assisted treatment programs. Since dextropropoxyphene is no longer marketed, dependence today involves diverted or legacy supplies — disclosing this to a healthcare provider allows appropriate management without the complications of ongoing prescribing.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Blue or grey lips, slowed or stopped breathing, unresponsiveness, seizures, or collapse within minutes to one hour of ingestion. Unlike most opioid overdoses, cardiac arrest is a primary risk — the person may have a pulse but develop a fatal irregular heart rhythm.
Immediate steps:
- 1. Call emergency services immediately — do not wait to see if they recover
- 2. Administer naloxone if available — it reverses respiratory depression but does NOT reverse cardiac toxicity[5]
- 3. Place in recovery position if breathing but unconscious
- 4. Begin CPR if no pulse or no breathing
- 5. Do NOT induce vomiting
What to tell the dispatcher: Name the substance (propoxyphene/Darvon/co-proxamol), approximate amount taken, time of ingestion, whether alcohol was involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agents: Naloxone reverses opioid respiratory depression but has no effect on propoxyphene/norpropoxyphene cardiac toxicity.[5] Cardiac toxicity requires hospital-level intervention — sodium bicarbonate for QRS widening, magnesium for QT prolongation. Hospital transport is essential even after naloxone administration.
Legal Status[edit]
Dextropropoxyphene has been withdrawn from pharmaceutical markets in all major jurisdictions.
| Jurisdiction | Status | Key provisions |
|---|---|---|
| United States | Withdrawn (November 19, 2010) | FDA requested voluntary market withdrawal citing QT prolongation at therapeutic doses; formerly DEA Schedule IV[9][30] |
| United Kingdom | Withdrawn (2005–2008) | CSM announced withdrawal January 2005; phased removal complete by 2008. Estimated 300–400 fewer overdose deaths per year[10] |
| European Union | Withdrawn (2008) | EMA recommended withdrawal of all marketing authorisations across member states |
| Ireland | Withdrawn (January 2006) | Distalgesic removed from Irish market[31] |
| Scotland | Withdrawn (2005–2008) | Followed UK CSM guidance; measurable reduction in poisoning deaths[32] |
| Australia | Cancelled from ARTG (~2010) | Dextropropoxyphene-containing products cancelled from Australian Register of Therapeutic Goods |
| India | Banned (2013) | Fixed-dose combinations banned by CDSCO |
| Canada | Status not confirmed | Regulatory status not verified in sources reviewedcitation needed |
Legal status changes frequently and varies by jurisdiction. This information reflects sources reviewed at time of writing and is not legal advice.
references
- [1]
- [2] ^abcLi Wan Po A, Zhang WY (1997) Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol — BMJ PMID:9437273
- [3] ^abcCollins GB, Kiefer KS (1981) Propoxyphene dependence: an update — Postgraduate Medicine PMID:7312731
- [4]
- [5]
- [6]